Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.52 |
| ▸ | HTR2B | P41595 | 10/20 | 0.52 |
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | HTR7 | P34969 | 6/20 | 0.46 |
| ▸ | HTR1A | P08908 | 3/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | LATS1 | O95835 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881120 | 1.00 | HTR2C (0.52) | HTR2CHTR2BHTR2AHTR7HTR1A | |
| SCHEMBL4887832 | 1.00 | HTR2C (0.52) | HTR2CHTR2BHTR2AHTR7HTR1A | |
| SCHEMBL5305264 | 0.87 | HTR2C (0.42) | HTR2CHTR2BHTR2AHTR7HTR1A | |
| SCHEMBL14442453 | 0.82 | HTR2C (0.46) | HTR2CHTR2BHTR2AHTR1AHTR6 | |
| SCHEMBL14442452 | 0.82 | HTR2C (0.46) | HTR2CHTR2BHTR2AHTR1AHTR6 | |
| SCHEMBL5358095 | 0.82 | HTR2C (0.47) | HTR2CHTR2BHTR2AHTR7HTR1A | |
| SCHEMBL5358102 | 0.82 | HTR2C (0.47) | HTR2CHTR2BHTR2AHTR7HTR1A | |
| SCHEMBL5305271 | 0.81 | HTR2C (0.40) | HTR2CHTR2BHTR2AHTR7HTR1A | |
| SCHEMBL4890371 | 0.80 | HTR2C (0.47) | HTR2CHTR2BHTR2A | |
| SCHEMBL5632098 | 0.80 | HTR2C (0.47) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120253036-A1 | AGENT FOR TREATING FIBROMYALGIA | ASTELLAS PHARMA INC. (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120253036-A1 | AGENT FOR TREATING FIBROMYALGIA | ASTELLAS PHARMA INC. (JP) | 2012-10-04 | — | — | US | disclosed |
| WO-2011071136-A1 | THERAPEUTIC AGENT FOR FIBROMYALGIA | アステラス製薬株式会社 (JP) | 2011-06-16 | — | — | WO | disclosed |
| US-20080255137-A1 | N-Biaryl and N-Arylheteroaryl 2-Substituted Piperazine Derivatives as Modulators of the 5ht2c Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255137-A1 | N-Biaryl and N-Arylheteroaryl 2-Substituted Piperazine Derivatives as Modulators of the 5ht2c Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255137-A1 | N-Biaryl and N-Arylheteroaryl 2-Substituted Piperazine Derivatives as Modulators of the 5ht2c Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1831188-A1 | N-BIARYL AND N-ARYLHETEROARYL 2-SUBSTITUTED PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065706-A9 | N-BIARYL AND N-ARYLHETEROARYL 2-SUBSTITUTED PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2006065706-A9 | N-BIARYL AND N-ARYLHETEROARYL 2-SUBSTITUTED PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2006065706-A1 | N-BIARYL AND N-ARYLHETEROARYL 2-SUBSTITUTED PIPERAZINE DERIVATIVES AS MODULATORS OF THE 5HT2C RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255137-A1 | N-Biaryl and N-Arylheteroaryl 2-Substituted Piperazine Derivatives as Modulators of the 5ht2c Receptor Useful for the Treatment of Disorders Related Thereto | HTR2C, HTR2A, HTR5A | HTR2C 1/4885HTR2B 5/4885HTR2A 2/4885 |
| US-20120253036-A1 | AGENT FOR TREATING FIBROMYALGIA | HTR2A, HTR2C, HTR3A | HTR2C 2/4885HTR2B 4/4885HTR2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.